Allena Pharmaceuticals

$1.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-1.46%) As of 9:07 AM EST pre-market

Why Robinhood?

You can buy or sell ALNA and other stocks, options, and ETFs commission-free!

About ALNA

Allena Pharmaceuticals, Inc. Common Stock, also called Allena Pharmaceuticals, is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA. The listed name for ALNA is Allena Pharmaceuticals, Inc. Common Stock.

CEO
Louis Brenner
Employees
83
Headquarters
Newton, Massachusetts
Founded
2011
Market Cap
51.69M
Price-Earnings Ratio
Dividend Yield
Average Volume
631.82K
High Today
$1.40
Low Today
$1.33
Open Price
$1.38
Volume
406.85K
52 Week High
$3.39
52 Week Low
$0.525

Collections

ALNA Earnings

-$0.57
-$0.38
-$0.19
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 15, Pre-Market

You May Also Like